Abstracts

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) seeks original papers that address scientific questions, demonstrate new research/developments or contain original scientific results specifically related to the treatment of patients with chronic lymphocytic leukemia (CLL).

The body of the abstract is limited to 700 words or less and must represent original work, although previously published work may be used to fulfill this requirement. Titles, authors, and affiliations are excluded from the total word count of 700 words. Submission of isolated case reports and hypotheses unsupported by data is discouraged. iwCLL reserves the right to reject any abstract for failure to comply with publication guidelines. Encore abstracts will be permitted, however those abstracts published or presented prior to December 1, 2020 will not be accepted. Late breaker abstracts will also be permitted but will only be considered for poster presentations. See Deadlines and Contact below for dates.

Abstract submissions must be made electronically through the submission page found HERE. Tables, figures, graphs, or images are allowed in the abstract submission and must be uploaded separately. The image/table uploads must not be larger than 10MB.  The deadline for abstract submission is 30 June 2021. You must withdraw abstracts prior to 23 August 2021. After this time, all accepted abstracts will be included in publication. In the case of abstract acceptance, the Presenting Author (or a Co-Author substitute) must be in attendance (virtually) to present during the meeting. All accepted abstracts will be reprinted for distribution in the online journal, Leukemia and Lymphoma. The XIX iwCLL meeting will include oral presentations for a select group of outstanding submissions and oral poster presentations, and a poster session for those accepted as a poster. Works accepted as oral presenters and oral poster presenters will receive complimentary registration to the main iwCLL meeting for September 17-20. Abstracts accepted as oral presentations to the Young Investigator Meeting will receive complimentary registration to the Young Investigator Meeting (YIM) being held on Friday, September 17^th.

Official development assistance (ODA) is defined by the OECD Development Assistance Committee (DAC) as government aid that promotes and specifically targets the economic development and welfare of developing countries. The DAC adopted ODA as the “gold standard” of foreign aid in 1969 and it remains the main source of financing for development aid.

Please see a list of countries here: (link to PDF)

Please note the following dates:

01 August 2021 – Abstract Late-Breakers Open
04 August 2021 – YIM & iwCLL Abstract Notifications
23 August 2021 – Abstract Late-Breakers Closed
23 August 2021 – Abstract Withdrawal Deadline
27 August 2021 – Abstract Titles and Authors Released on Website
01 September 2021 – Late-Breakers Notifications
13 September 2021 – Late-Breakers and Full Abstracts Released on Virtual Platform

Any questions regarding abstract submissions should be sent to iwcll@bioascend.com

Before beginning your abstract submission, you will be asked to login or create an account.

The following information is required in order to submit an abstract.

The Submitting/Presenting Author must provide complete contact information in the Abstract Submission System including:

• Full name
• Degree/Credentials
• Institution
• Address
• Telephone number
• Email address
• Profile image (optional)
• Biography (This is required, but if you do not wish to add a bio, please type N/A)

The Submitting/Presenting Author will receive all future correspondence from iwCLL regarding the status of the abstract, instructions regarding presentation and publishing.

Presenting Authors must also provide co-author information on the first page of the Abstract Submission System including:

• Full name
• Email address
• Author Role

Important: Author and Co-author details should be excluded from the abstract upload.

Submissions will be editable prior to the June deadline date when you log back into the Abstract Submission System.

• Abstract Title (300 character limit including spaces)

• Abstract Text
  • 700-word limit
  • May include two (2) tables, figures, graphs, or images 
  • The upload document of the tables/images may not be larger than 10 MB
  • Structure is permitted, but not required: Introduction, Methods, Results and Conclusions
  • Multiple paragraphs are permitted
  • References are to be cited within the text, not as footnotes
  • Abstracts must be in English
• Identification of which meeting submission is intended for:
  • Young Investigator Meeting
  • iwCLL Main Meeting
  • Both Young Investigator Meeting & iwCLL Main Meeting
• Abstract Type
  • General Abstract: All types of clinical-based and laboratory-based research projects relating to CLL and related B-cell lymphoproliferative disorders are eligible for submission.
  • Encore: Abstracts containing updated data with respect to a previous presentation may be submitted. Authors must supply information regarding the original presentation for identification and comparison purposes, indicating the name of the meeting, year and/or publication number. Encores will not be accepted if published or presented prior to December 1, 2020
  • Trials In Progress: Indicate if the trial has been registered, the registry, and the registration number.
• Category: Please select one of the below that your abstract is related to. The category will be used as the initial basis for review of your abstract.
  • Laboratory based research or
  • Clinical-based research
  • Real World Evidence
• Topic: Please select one of the below main topics that your abstract is related to. Topics will be used to best place selected abstracts within the program agenda. Examples are included but are not restricted to these.
  • Pathogenesis of CLL
    • Molecular Pathogenesis of CLL – Genomics and Proteomics
    • Molecular Pathogenesis of CLL – Microenvironment and Signaling
    • Clonal Dynamics, Competition, and Disease Evolution
  • Approach considerations and treatment options in CLL
    • Prognostication and Prediction in the Era of Novel Drugs
    • MRD – Methods and Clinical Application
    • First-line therapy of CLL
    • Treatment of relapsed/refractory CLL
  • Rationally Designed Therapy on the Horizon in CLL
    • New Agents in CLL Clinical Trials
    • Immunotherapy of CLL
• Other submission questions:
  • Keywords (leukemia, relapsed/refractory, biomarker, etc)
  • Research funding